Joseph Schwartz

Why InflaRx Shares Are Ripping Higher Thursday

Sarepta Falls To 10-Month Low After DMD Gene Therapy Study Misses Primary Endpoint

Imara Analyst Says Buy The Weakness Ahead Of Multiple 2021 Data Readouts

Sarepta Falls To 10-Month Low After DMD Gene Therapy Study Misses Primary Endpoint

Imara Analyst Says Buy The Weakness Ahead Of Multiple 2021 Data Readouts

6 Gene Therapy M&A Targets On The Radar

There's Good Cause To Be Excited About Amicus Therapeutics Clinical Program

6 Gene Therapy M&A Targets On The Radar

There's Good Cause To Be Excited About Amicus Therapeutics Clinical Program

What's The Thesis On ProQR Now, After Promising Phase 1 Data?

FDA Letter On Intercept Pharma Doesn't Include Black Box Warning Label...Yet